{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:52Z","timestamp":1789726312167,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T00:00:00Z","timestamp":1478649600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12020-016-1166-4","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T04:32:53Z","timestamp":1478665973000},"page":"464-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure"],"prefix":"10.1007","volume":"57","author":[{"given":"F.","family":"Arturi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Succurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cloro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Perticone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Perticone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,9]]},"reference":[{"key":"1166_CR1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2337\/diacare.28.3.612","volume":"28","author":"IS Thrainsdottir","year":"2005","unstructured":"I.S. Thrainsdottir, T. Aspelund, G. Thorgeirsson, V. Gudnason, T. Hardarson, K. Malmberg, G. Sigurdsson, L. Ryd\u00e8n, The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 28, 612\u2013616 (2005)","journal-title":"Diabetes Care."},{"key":"1166_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1475-2840-9-63","volume":"9","author":"W Dinh","year":"2010","unstructured":"W. Dinh, M. Lankisch, W. Nickl, D. Scheyer, T. Scheffold, F. Kramer, F. Kramer, T. Krahn, R.M. Klein, M.C. Barroso, Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. Cardiovasc. Diabetol. 9, 63\u201374 (2010)","journal-title":"Cardiovasc. Diabetol."},{"key":"1166_CR3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"S. Rubler, J. Dlugash, Y.Z. Yuceoglu, T. Kumral, A.D. Branwood, A. Grishman, New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595\u2013602 (1972)","journal-title":"Am. J. Cardiol."},{"key":"1166_CR4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0022-2828(08)80016-8","volume":"27","author":"B Rodrigues","year":"1995","unstructured":"B. Rodrigues, M.C. Cam, J.H. McNeill, Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 27, 169\u2013179 (1995)","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1166_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/hrt.2010.214031","volume":"97","author":"LH Opie","year":"2011","unstructured":"L.H. Opie, D.M. Yellon, B.J. Gersh, Controversies in the cardiovascular management of type 2 diabetes. Heart. 97, 6\u201314 (2011)","journal-title":"Heart."},{"key":"1166_CR6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.hfc.2012.06.007","volume":"8","author":"JD Schilling","year":"2012","unstructured":"J.D. Schilling, D.L. Mann, Diabetic cardiomyopathy: bench to bedside. Heart Fail. Clin. 8, 619\u2013631 (2012)","journal-title":"Heart Fail. Clin."},{"key":"1166_CR7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2007.03.029","volume":"154","author":"DL Bhatt","year":"2007","unstructured":"D.L. Bhatt, D.P. Chew, C. Grines, D. Mukherjee, M. Leesar, I.C. Gilchrist, J.C. Corbelli, J.C. Blankenship, A. Eres, S. Steinhubl, W.A. Tan, J.R. Resar, A. AlMahameed, A. Abdel-Latif, W.H. Tang, D. Brennan, E. McErlean, S.L. Hazen, E.J. Topol, Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study. Am. Heart J. 154, 137\u2013143 (2007)","journal-title":"Am. Heart J."},{"key":"1166_CR8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lef\u00e8bvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Kor\u00e0nyi, M. Laakso, M. Mok\u00e0n, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Skrha, U. Smith, J. taton; PROactive Investigators., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 366, 1279\u20131289 (2005)","journal-title":"Lancet."},{"key":"1166_CR9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","volume":"370","author":"RM Lago","year":"2007","unstructured":"R.M. Lago, P.P. Singh, R.W. Nesto, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 370, 1129\u20131136 (2007)","journal-title":"Lancet."},{"key":"1166_CR10","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","volume":"28","author":"DT Eurich","year":"2005","unstructured":"D.T. Eurich, S.R. Majumdar, F.A. McAlister, R.T. Tsuyuki, J.A. Johnson, Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 28, 2345\u20132351 (2005)","journal-title":"Diabetes Care."},{"key":"1166_CR11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/dmrr.480","volume":"21","author":"GA Nichols","year":"2005","unstructured":"G.A. Nichols, C.E. Koro, C.M. Gullion, S.A. Ephross, J.B. Brown, The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab. Res. Rev. 21, 51\u201357 (2005)","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"335","key":"1166_CR12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.39314.620174.80","volume":"8","author":"DT Eurich","year":"2007","unstructured":"D.T. Eurich, F.A. McAlister, D.F. Blackburn, S.R. Majumdar, R.T. Tsuyuki, J. Varney, J.A. Johnson, Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Br. Med. J. 8(335), 497 (2007)","journal-title":"Br. Med. J."},{"key":"1166_CR13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz; SAVOR-TIMI 53 Steering Committee and Investigators., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317\u20131326 (2013)","journal-title":"N. Engl. J. Med."},{"key":"1166_CR14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad; EXAMINE Investigators., Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327\u20131335 (2013)","journal-title":"N. Engl. J. Med."},{"key":"1166_CR15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman; TECOS Study Group., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232\u2013242 (2015)","journal-title":"N. Engl. J. Med."},{"key":"1166_CR16","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"M.A. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H.C. Gerstein, L.V. K\u00f8ber, F.C. Lawson, L. Ping, X. Wei, E.F. Lewis, A.P. Maggioni, J.J. McMurray, J.L. Probstfield, M.C. Riddle, S.D. Solomon, J.C. Tardif; ELIXA Investigators., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247\u20132257 (2015)","journal-title":"N. Engl. J. Med."},{"key":"1166_CR17","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi; EMPA REG OUTCOME Investigators., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015)","journal-title":"N. Engl. J. Med."},{"key":"1166_CR18","unstructured":"S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse; LEADER Steering Committee on Behalf of the LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. [Epub ahead of print] 375, 311\u201322 (2016)"},{"key":"1166_CR19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"D.J. Drucker, M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368, 1696\u20131705 (2006)","journal-title":"Lancet."},{"key":"1166_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"JR Ussher","year":"2012","unstructured":"J.R. Ussher, D.J. Drucker, Cardiovascular biology of the incretin system. Endocr. Rev. 33, 187\u2013215 (2012)","journal-title":"Endocr. Rev."},{"key":"1166_CR21","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.clinthera.2009.11.034","volume":"31","author":"E Montanya","year":"2009","unstructured":"E. Montanya, G. Sesti, A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin. Ther. 31, 2472\u20132488 (2009)","journal-title":"Clin. Ther."},{"key":"1166_CR22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha, M. Ztravkovic, M. During, D.R. Matthews; LEAD-2 Study Group., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 32, 84\u201390 (2009)","journal-title":"Diabetes Care."},{"key":"1166_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. Blonde; LEAD-6 Study Group., A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomized, 26-week, open-label trial (LEAD-6). Lancet. 374, 39\u201347 (2009)","journal-title":"Lancet."},{"key":"1166_CR24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"RE Amori","year":"2007","unstructured":"R.E. Amori, J. Lau, A.G. Pittas, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 298, 194\u2013206 (2007)","journal-title":"JAMA."},{"key":"1166_CR25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCULATIONAHA.107.735795","volume":"117","author":"SE Inzucchi","year":"2008","unstructured":"S.E. Inzucchi, D.K. McGuire, New drugs for the treatment of diabetes. Part II: incretin-based therapy and beyond. Circulation 117, 574\u2013584 (2008)","journal-title":"Circulation"},{"key":"1166_CR26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3132\/dvdr.2004.005","volume":"1","author":"I Thrainsdottir","year":"2004","unstructured":"I. Thrainsdottir, K. Malmberg, A. Olsson, M. Gutniak, L. Ryd\u00e9n, Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res. 1, 40\u201343 (2004)","journal-title":"Diab. Vasc. Dis. Res."},{"key":"1166_CR27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"L.A. Nikolaidis, S. Mankad, G. Sokos, G. Miske, A. Shah, D. Elahi, R.P. Shannon, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 109, 962\u2013965 (2004)","journal-title":"Circulation."},{"key":"1166_CR28","doi-asserted-by":"crossref","first-page":"694e699","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"G Sokos","year":"2006","unstructured":"G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, R.P. Shannon, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Cardiac. Fail. 12, 694e699 (2006)","journal-title":"J. Cardiac. Fail."},{"issue":"14","key":"1166_CR29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-015-0259-3","volume":"8","author":"LM McCormick","year":"2015","unstructured":"L.M. McCormick, P.M. Heck, L.S. Ring, A.C. Kydd, S.J. Clarke, S.P. Hoole, D.P. Dutka, Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc. Diabetol. 8(14), 102 (2015)","journal-title":"Cardiovasc. Diabetol."},{"key":"1166_CR30","doi-asserted-by":"publisher","unstructured":"W.R. Chen, X.Q. Shen, Y. Zhang, Y.D. Chen, G. Qian, J. Wang, J.J. Yang, Z.F. Wang, F. Tian, Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 52, 516\u2013526 (2015) doi:\n                        10.1007\/s12020-015-0798-0","DOI":"10.1007\/s12020-015-0798-0"},{"issue":"3","key":"1166_CR31","doi-asserted-by":"publisher","first-page":"H1096","DOI":"10.1152\/ajpheart.00930.2009","volume":"298","author":"M Halbirk","year":"2010","unstructured":"M. Halbirk, H. N\u00f8rrelund, N. M\u00f8ller, J.J. Holst, O. Schmitz, R. Nielsen, J.E. Nielsen-Kudsk, S.S. Nielsen, T.T. Nielsen, H. Eiskjaer, H.E. B\u00f8tker, H. Wiggers, Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart. Circ. Physiol. 298(3), H1096\u2013102 (2010). doi:\n                        10.1152\/ajpheart.00930.2009","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"1166_CR32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-011-2440-x","volume":"55","author":"D Nathanson","year":"2012","unstructured":"D. Nathanson, B. Ullman, U. L\u00f6fstr\u00f6m, A. Hedman, M. Frick, A. Sj\u00f6holm, T. Nystr\u00f6m, Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 55, 926\u2013935 (2012). doi:\n                        10.1007\/s00125-011-2440-x","journal-title":"Diabetologia."},{"key":"1166_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12020-014-0175-4","volume":"47","author":"N Mikhail","year":"2014","unstructured":"N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine. 47, 21\u201328 (2014). doi:\n                        10.1007\/s12020-014-0175-4","journal-title":"Endocrine."},{"key":"1166_CR34","unstructured":"K.B. Margulies, K.J. Anstrom, M.M. Redfield, et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). American Heart Association 2015 Scientific Sessions; 8 November 2015; Orlando, Florida. Abstract 20102 (2015)"},{"key":"1166_CR35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"MH Noyan-Ashraf","year":"2009","unstructured":"M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, D.J. Drucker, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975\u2013983 (2009)","journal-title":"Diabetes"},{"key":"1166_CR36","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1152\/ajpheart.00885.2010","volume":"300","author":"S Ravassa","year":"2011","unstructured":"S. Ravassa, A. Zudaire, R.D. Carr, J. D\u00edez, Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 300, 1361\u20131372 (2011)","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1166_CR37","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, M. Husain, Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and \u2013independent pathways. Circulation. 117, 2340\u20132350 (2008)","journal-title":"Circulation."},{"key":"1166_CR38","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/jpet.106.100982","volume":"317","author":"T Zhao","year":"2006","unstructured":"T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.T. Shen, R.P. Shannon, Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317, 1106\u20131113 (2006)","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1166_CR39","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1152\/ajpendo.00373.2007","volume":"293","author":"A Basu","year":"2007","unstructured":"A. Basu, N. Charkoudian, W. Schrage, R.A. Rizza, R. Basu, M.J. Joyner, Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293, 1289\u20131295 (2007)","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1166_CR40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","volume":"110","author":"LA Nikolaidis","year":"2004","unstructured":"L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, L. Zourelias, C. Stolarski, Y.T. Shen, R.P. Shannon, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 110, 955\u2013961 (2004)","journal-title":"Circulation."},{"key":"1166_CR41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2337\/dc10-1949","volume":"34","author":"A Ceriello","year":"2011","unstructured":"A. Ceriello, K. Esposito, R. Testa, A.R. Bonfigli, M. Marra, D. Giugliano, The possible protective role of glucagon like peptide 1 on endothelium during the meal and evidence for an \u201cendothelial resistance\u201d to glucagon-like peptide 1 in diabetes. Diabetes Care. 34, 697\u2013702 (2011)","journal-title":"Diabetes Care."},{"key":"1166_CR42","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s12020-014-0246-6.","volume":"47","author":"K Okada","year":"2014","unstructured":"K. Okada, K. Kotani, H. Yagyu, A. Ando, J. Osuga, S. Ishibashi, Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine. 47, 962\u2013964 (2014). doi:\n                        10.1007\/s12020-014-0246-6.","journal-title":"Endocrine."},{"key":"1166_CR43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","volume":"55","author":"KE Mayo","year":"2003","unstructured":"K.E. Mayo, L.J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, D.J. Drucker, International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev 55, 167\u2013194 (2003)","journal-title":"Pharmacol. Rev"},{"key":"1166_CR44","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","volume":"89","author":"B Thorens","year":"1992","unstructured":"B. Thorens, Expression cloning of the pancreatic-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci USA 89, 8641\u20138645 (1992)","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"1166_CR45","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1152\/ajpheart.00347.2005","volume":"289","author":"LA Nikolaidis","year":"2005","unstructured":"L.A. Nikolaidis, D. Elahi, Y.T. Shen, R.P. Shannon, Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, 2401\u20132408 (2005)","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1166_CR46","first-page":"952","volume":"80","author":"CF Deacon","year":"1995","unstructured":"C.F. Deacon, A.H. Johnsen, J.J. Holst, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952\u2013957 (1995)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1166_CR47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2010.01316.x","volume":"13","author":"E Tomas","year":"2011","unstructured":"E. Tomas, J.A. Wood, V. Stanojevic, J.F. Habener, Glucagon-like peptide-1(9-36) amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diabetes Obes. Metab. 13, 26\u201333 (2011)","journal-title":"Diabetes Obes. Metab."},{"key":"1166_CR48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCHEARTFAILURE.108.766402","volume":"1","author":"IB Poornima","year":"2008","unstructured":"I.B. Poornima, S. Bhashyam, P. Parikh, H. Bolukoglu, R. Shannon, Chronic glucagon-like peptide-1 infusion sustains left ventricular function and prolongs survival in spontaneously hypertensive, heart failure prone rats. Circ. Heart Fail. 1, 153\u2013160 (2008)","journal-title":"Circ. Heart Fail."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-1166-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1166-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1166-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T08:38:16Z","timestamp":1503909496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-1166-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-1166-4","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,9]]}}}